Newly Diagnosed Standard Risk Medulloblastoma Study

Newly Diagnosed Standard Risk Medulloblastoma Study

Share this:

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial.


COG # ACNS0331


This study wants to determine whether reducing the craniospinal dose of radiation therapy in children 3-7 years of age does not compromise event-free survival and overall survival as compared to treatment with a reduced dose of craniospinal radiation; and to determine if reducing the irradiated volume of the primary site tumor boost from the whole posterior fossa to the tumor bed only will not compromise event-free and overall survival.


  • Patients must be greater than or equal to three years and less than 22 years at the time of diagnosis.
  • The presence of a posterior fossa medulloblastoma as determined by institutional pathologic evaluation.
  • Preoperative and postoperative cranial MRI with and without contrast must be available.
  • Patients must have adequate organ function as defined by the protocol.

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376